Zai Lab
Clarence Eng is an experienced professional in clinical operations, currently serving as Senior Director of Clinical Operations at Zai Lab since August 2021. Prior to this role, Clarence held the position of Sr Director of Clinical Operations at Terns Pharmaceuticals from September 2019 to August 2021. Previous experience includes serving as Director of Clinical Operations at Five Prime Therapeutics, Inc. from September 2017 to August 2019, and as Senior Clinical Program Manager at Gilead Sciences from June 2014 to August 2017. Clarence's career began at InterMune as a Clinical Research Associate 2 from August 2002 to February 2004, followed by a decade at Threshold Pharmaceuticals, where Clarence advanced to Associate Director of Clinical Operations.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.